Literature DB >> 27128604

Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.

Frank Stifft1, Nasrullah Undre, Johannes P van Hooff, Maarten H L Christiaans.   

Abstract

BACKGROUND: The once-daily Tacrolimus formulation (Tac ONCE-DAILY) has to be taken on an empty stomach. This is inconvenient for patients and may hamper compliance. The influence of food intake on the exposure of Tac ONCE-DAILY is unknown in transplant recipients. We compared the pharmacokinetics (PKs) of Tac ONCE-DAILY in stable kidney transplant recipients under fasted and fed conditions.
METHODS: In an open-label, single-center, cross-over PK study, 27 stable kidney white transplant recipients (17 male, 10 female) treated with Tac ONCE-DAILY under fasted conditions were enrolled. Two 10-point 24-hour blood concentration time profiles [area under the blood concentration time curve from time 0 to 24 hours (AUC0-24)] were collected under steady state conditions. The primary objective was to investigate the effect of food on the PKs and relative bioavailability of Tac ONCE-DAILY.
RESULTS: Twenty-seven stable renal transplant patients provided 1 AUC0-24 under fasted and fed conditions, respectively. AUC0-24, C24, and Cmax, were lower in the fed state and Tmax was 1 hour postponed. The 90% confidence interval ratio (fed: fasted) for AUC0-24 was 0.81-0.91 and for C24 0.82-0.92 (both P < 0.001). The majority (60%) had no significant change, but the change in AUC0-24 ranged from -38% to +29%. One trough level was below the target range after fed intake.
CONCLUSIONS: When Tac ONCE-DAILY is ingested with standard continental breakfast, AUC0-24 and C24 decrease overall, with C24 in the therapeutic range in almost all patients. The convenient fed intake could promote therapy adherence. Given the possible significant change in exposure, we advise monitoring of the tacrolimus trough level 1 week after fed ingestion of Tac ONCE-DAILY.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27128604     DOI: 10.1097/FTD.0000000000000311

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts.

Authors:  Frank Stifft; Franciscus Vandermeer; Cees Neef; Sander van Kuijk; Maarten H L Christiaans
Journal:  Eur J Clin Pharmacol       Date:  2020-02-04       Impact factor: 2.953

Review 2.  Clinical aspects of tacrolimus use in paediatric renal transplant recipients.

Authors:  Agnieszka Prytuła; Teun van Gelder
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

3.  High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation.

Authors:  Cristina Dopazo; Itxarone Bilbao; Sonia García; Concepción Gómez-Gavara; Mireia Caralt; Isabel Campos-Varela; Lluis Castells; Ernest Hidalgo; Francisco Moreso; Bruno Montoro; Ramón Charco
Journal:  Clin Transl Sci       Date:  2022-04-19       Impact factor: 4.438

4.  A modified LC-MS/MS method for the detection of whole blood tacrolimus and its clinical value in Chinese kidney transplant patients.

Authors:  Ke-Wei Yu; Bing-Ling Li; Ying-Shi Yuan; Jia-Min Liao; Wei-Kang Li; Heng Dong; Pei-Feng Ke; Xing Jin; Lu Chen; Jing-Jing Zhao; Heng Wang; Shun-Wang Cao; Wei-Ye Chen; Xian-Zhang Huang; Bei-Bei Zhao; Chun-Min Kang
Journal:  Heliyon       Date:  2022-08-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.